Developing therapeutic strategies aimed at reviving the latent activity of wild-type p53 in cancer cells represents an extremely valuable clinical opportunity to exploit the innate tumour suppressive function of this fundamental cellular protein. This evidence concerns the gene TP53 and cancer.